Multicenter Evaluation of Neoadjuvant and Induction Gemcitabine-Carboplatin versus Gemcitabine-Cisplatin Followed by Radical Cystectomy for Muscle-Invasive Bladder Cancer
dc.contributor.author | Einerhand, Sarah MH | |
dc.contributor.author | Black, Anna J | |
dc.contributor.author | Zargar, Homayoun | |
dc.contributor.author | Fairey, Adrian S. | |
dc.contributor.author | Dinney, Colin P | |
dc.contributor.author | Mir, Maria C | |
dc.contributor.author | Krabbe, Laura-Maria | |
dc.contributor.author | Cookson, Michael S. | |
dc.contributor.author | Jacobson, Niels-Erik | |
dc.contributor.author | Montgomery, Jeffrey S | |
dc.contributor.author | Vasdev, Nikhil | |
dc.contributor.author | Yu, Evan Y | |
dc.contributor.author | Xylinas, Evanguelos | |
dc.contributor.author | Kassouf, Wassim | |
dc.contributor.author | Dall’Era, Marc A. | |
dc.contributor.author | Sridhar, Srikala S. | |
dc.contributor.author | McGrath, Jonathan S | |
dc.contributor.author | Aning, Jonathan | |
dc.contributor.author | Shariat, Shahrokh F | |
dc.contributor.author | Wright, Jonathan L. | |
dc.contributor.author | Thorpe, Andrew C. | |
dc.contributor.author | Morgan, Todd M | |
dc.contributor.author | Holzbeierlein, Jeff M. | |
dc.contributor.author | Bivalacqua, Trinity J | |
dc.contributor.author | North, Scott | |
dc.contributor.author | Barocas, Daniel A. | |
dc.contributor.author | Lotan, Yair | |
dc.contributor.author | Grivas, Petros | |
dc.contributor.author | Garcia, Jorge A | |
dc.contributor.author | Stephenson, Andrew J | |
dc.contributor.author | Shah, Jay B | |
dc.contributor.author | Daneshmand, Simak | |
dc.contributor.author | Zargar-Shoshtari, Kamran | |
dc.contributor.author | Spiess, P. E. | |
dc.contributor.author | van Rhijn, Bas W | |
dc.contributor.author | Black, Peter C. | |
dc.contributor.author | Mertens, L. S. | |
dc.date.accessioned | 2022-10-25T13:30:02Z | |
dc.date.available | 2022-10-25T13:30:02Z | |
dc.date.issued | 2022-09-28 | |
dc.identifier.citation | Einerhand , S MH , Black , A J , Zargar , H , Fairey , A S , Dinney , C P , Mir , M C , Krabbe , L-M , Cookson , M S , Jacobson , N-E , Montgomery , J S , Vasdev , N , Yu , E Y , Xylinas , E , Kassouf , W , Dall’Era , M A , Sridhar , S S , McGrath , J S , Aning , J , Shariat , S F , Wright , J L , Thorpe , A C , Morgan , T M , Holzbeierlein , J M , Bivalacqua , T J , North , S , Barocas , D A , Lotan , Y , Grivas , P , Garcia , J A , Stephenson , A J , Shah , J B , Daneshmand , S , Zargar-Shoshtari , K , Spiess , P E , van Rhijn , B W , Black , P C & Mertens , L S 2022 , ' Multicenter Evaluation of Neoadjuvant and Induction Gemcitabine-Carboplatin versus Gemcitabine-Cisplatin Followed by Radical Cystectomy for Muscle-Invasive Bladder Cancer ' , World Journal of Urology . https://doi.org/10.1007/s00345-022-04160-7 | |
dc.identifier.issn | 0724-4983 | |
dc.identifier.uri | http://hdl.handle.net/2299/25839 | |
dc.description | © 2022 Springer Nature Switzerland AG. This is the accepted manuscript version of an article which has been published in final form at https://doi.org/10.1007/s00345-022-04160-7 | |
dc.description.abstract | PurposeCisplatin-based chemotherapy followed by radical cystectomy (RC) is recommended in patients with muscle-invasive bladder cancer (MIBC). However, up to 50% of patients are cisplatin-ineligible. The aim of this study was to compare clinical outcomes after ≥3 cycles of preoperative gemcitabine-carboplatin (gem-carbo) versus gemcitabine-cisplatin (gem-cis). Methods We identified 1865 patients treated at 19 centers between 2000 and 2013. Patients were included if they had received ≥3 cycles of neoadjuvant (cT2-4aN0M0) or induction (cTanyN+M0) gem-carbo or gem-cis followed by RC. Results We included 747 patients treated with gem-carbo (n=147) or gem-cis (n=600). Patients treated with gem carbo had a higher Charlson Comorbidity Index (p=0.016) and more clinically node-positive disease (32% 88 versus 20%; p=0.013). The complete pathological response (pCR; ypT0N0) rate did not significantly differ between gem-carbo and gem-cis (20.7% versus 22.1%; p=0.73). Chemotherapeutic regimen was not significantly associated with pCR (OR: 0.99 [95%CI, 0.61-1.59]; p=0.96), overall survival (OS) (HR: 1.20 91 [95%CI, 0.85-1.67]; p=0.31), or cancer-specific survival (CSS) (HR: 1.35 [95%CI, 0.93-1.96]; p=0.11). Median OS of patients treated with gem-carbo and gem-cis was 28.6 months (95%CI 18.1-39.1) and 45.1 months (95%CI 32.7-57.6)(p=0.18), respectively. Median CSS of patients treated with gem-carbo and gem-cis was 28.8 months (95%CI 9.8-47.8) and 71.0 months (95%CI median not reached)(p=0.02), respectively. Subanalyses of the neoadjuvant and induction setting did not show significant survival differences. 4 Conclusion Our results show that a subset of cisplatin-ineligible patients with MIBC achieve pCR on gem-carbo and that survival outcomes seem comparable to gem-cis provided patients are able to receive ≥3 cycles and undergo RC. | en |
dc.format.extent | 233175 | |
dc.language.iso | eng | |
dc.relation.ispartof | World Journal of Urology | |
dc.title | Multicenter Evaluation of Neoadjuvant and Induction Gemcitabine-Carboplatin versus Gemcitabine-Cisplatin Followed by Radical Cystectomy for Muscle-Invasive Bladder Cancer | en |
dc.contributor.institution | Centre for Health Services and Clinical Research | |
dc.contributor.institution | Basic and Clinical Science Unit | |
dc.contributor.institution | Extracellular Vesicle Research Unit | |
dc.contributor.institution | School of Life and Medical Sciences | |
dc.contributor.institution | Department of Clinical, Pharmaceutical and Biological Science | |
dc.description.status | Peer reviewed | |
dc.date.embargoedUntil | 2023-09-28 | |
rioxxterms.versionofrecord | 10.1007/s00345-022-04160-7 | |
rioxxterms.type | Journal Article/Review | |
herts.preservation.rarelyaccessed | true |